Gregg S Nelson
Overview
Explore the profile of Gregg S Nelson including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
442
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Smith D, Kang E, Nelson G, Lee C, Kobel M, Aubrey C
Gynecol Oncol Rep
. 2024 Jul;
54:101447.
PMID: 39055290
Objective: This study aims to investigate the relationship between body mass index (BMI) and molecular subtypes of endometrial carcinoma using an immunohistochemistry (IHC)-based classification approach. Methods: We analyzed a consecutive...
2.
Kobel M, Kang E, Lee S, Ogilvie T, Terzic T, Wang L, et al.
J Pathol Clin Res
. 2024 Jul;
10(4):e12389.
PMID: 38970797
Mesonephric-type (or -like) adenocarcinomas (MAs) of the ovary are an uncommon and aggressive histotype. They appear to arise through transdifferentiation from Müllerian lesions creating diagnostic challenges. Thus, we aimed to...
3.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
Clin Cancer Res
. 2024 Jun;
30(16):3481-3498.
PMID: 38837893
Purpose: The purpose of this study was to evaluate RB1 expression and survival across ovarian carcinoma histotypes and how co-occurrence of BRCA1 or BRCA2 (BRCA) alterations and RB1 loss influences...
4.
Saner F, Takahashi K, Budden T, Pandey A, Ariyaratne D, Zwimpfer T, et al.
medRxiv
. 2023 Nov;
PMID: 37986741
Background: Somatic loss of the tumour suppressor RB1 is a common event in tubo-ovarian high-grade serous carcinoma (HGSC), which frequently co-occurs with alterations in homologous recombination DNA repair genes including...
5.
Kobel M, Yang R, Kang E, Al-Shamma Z, Cook L, Kinloch M, et al.
Gynecol Oncol
. 2023 Oct;
178:80-88.
PMID: 37820398
Objective: Inhibition of the MAPK pathway by MEK inhibitors (MEKi) is currently a therapeutic standard in several cancer types, including ovarian low-grade serous carcinoma (LGSC). A common MAPK pathway alteration...
6.
Kobel M, Kang E, Weir A, Rambau P, Lee C, Nelson G, et al.
J Pathol Clin Res
. 2023 Mar;
9(3):208-222.
PMID: 36948887
Our objective was to test whether p53 expression status is associated with survival for women diagnosed with the most common ovarian carcinoma histotypes (high-grade serous carcinoma [HGSC], endometrioid carcinoma [EC],...
7.
Kang E, Weir A, Meagher N, Farrington K, Nelson G, Ghatage P, et al.
Cancer
. 2022 Dec;
129(5):697-713.
PMID: 36572991
Background: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression...
8.
Weir A, Kang E, Meagher N, Nelson G, Ghatage P, Lee C, et al.
Br J Cancer
. 2022 Nov;
128(1):137-147.
PMID: 36323878
Background: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied...
9.
Parrish 2nd R, Findley R, Elias K, Kramer B, Johnson E, Gramlich L, et al.
Ann Med Surg (Lond)
. 2022 Jan;
73:103178.
PMID: 35003725
Background: Pharmacotherapy prophylaxis embedded in Enhanced Recovery After Surgery (ERAS®) protocols is largely unknown because data related to agent choice, dosing, timing, and duration of treatment currently are not collected...
10.
Heinze K, Nazeran T, Lee S, Kramer P, Cairns E, Chiu D, et al.
J Pathol
. 2021 Dec;
256(4):388-401.
PMID: 34897700
ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are...